Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
-
CAMBRIDGE, Mass., Nov. 12, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
-
CAMBRIDGE, Mass., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
-
CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
-
CAMBRIDGE, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
-
VY-AADC for advanced Parkinson’s disease on track for start of global, pivotal phase 2-3 program Integration of novel capsid and delivery optimization efforts expected to result in two IND filings...
-
Voyager to gain worldwide rights to VY-AADC program for advanced Parkinson’s disease Global, pivotal Phase 2-3 program for VY-AADC on track to dose the first patient during the second quarter of 2018...
-
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases,...
-
New data with novel AAV gene therapy capsids demonstrate widespread gene transfer to the brain and spinal cord of non-human primates after a single intravenous administration Additional studies at...
-
CAMBRIDGE, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...